全文获取类型
收费全文 | 3244036篇 |
免费 | 265521篇 |
国内免费 | 9380篇 |
专业分类
耳鼻咽喉 | 45825篇 |
儿科学 | 102009篇 |
妇产科学 | 87282篇 |
基础医学 | 451693篇 |
口腔科学 | 92759篇 |
临床医学 | 299142篇 |
内科学 | 640767篇 |
皮肤病学 | 70191篇 |
神经病学 | 272753篇 |
特种医学 | 130197篇 |
外国民族医学 | 1118篇 |
外科学 | 494279篇 |
综合类 | 77735篇 |
现状与发展 | 3篇 |
一般理论 | 1347篇 |
预防医学 | 267461篇 |
眼科学 | 74499篇 |
药学 | 236732篇 |
9篇 | |
中国医学 | 5798篇 |
肿瘤学 | 167338篇 |
出版年
2018年 | 33661篇 |
2016年 | 29836篇 |
2015年 | 33517篇 |
2014年 | 47716篇 |
2013年 | 72513篇 |
2012年 | 94091篇 |
2011年 | 100217篇 |
2010年 | 60362篇 |
2009年 | 58145篇 |
2008年 | 94432篇 |
2007年 | 100748篇 |
2006年 | 101689篇 |
2005年 | 99141篇 |
2004年 | 95171篇 |
2003年 | 92152篇 |
2002年 | 89709篇 |
2001年 | 148181篇 |
2000年 | 153243篇 |
1999年 | 129085篇 |
1998年 | 39188篇 |
1997年 | 35218篇 |
1996年 | 35537篇 |
1995年 | 34966篇 |
1994年 | 32799篇 |
1993年 | 30699篇 |
1992年 | 105525篇 |
1991年 | 102285篇 |
1990年 | 98688篇 |
1989年 | 94550篇 |
1988年 | 87967篇 |
1987年 | 86801篇 |
1986年 | 82151篇 |
1985年 | 79036篇 |
1984年 | 60267篇 |
1983年 | 51407篇 |
1982年 | 31814篇 |
1981年 | 28625篇 |
1980年 | 26940篇 |
1979年 | 56087篇 |
1978年 | 40150篇 |
1977年 | 33842篇 |
1976年 | 31639篇 |
1975年 | 33187篇 |
1974年 | 40411篇 |
1973年 | 38450篇 |
1972年 | 36022篇 |
1971年 | 33361篇 |
1970年 | 31161篇 |
1969年 | 29033篇 |
1968年 | 26711篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Mark S. Wallace Steven G. Charapata Robert Fisher Michael Byas‐Smith Peter S. Staats Martha Mayo Dawn McGuire David Ellis 《Neuromodulation》2006,9(2):75-86
Objective. The safety and efficacy of intrathecal (IT) ziconotide was studied in a randomized, double‐blind, placebo‐controlled trial. Materials and Methods. Patients (169 ziconotide, 86 placebo) with severe chronic nonmalignant pain unresponsive to conventional therapy and a visual analog scale of pain intensity (VASPI score) ≥ 50 mm were treated over a 6‐day period in an inpatient hospital setting. Initial starting dose was 0.4 µg/hour and was titrated to analgesia or intolerance (maximum dose 7.0 µg/hour). The starting and maximum doses were reduced to 0.1 µg/hour and 2.4 µg/hour, respectively, due to adverse events (AEs). Results. The mean percent reduction in VASPI score from baseline was 31.2% and 6.0% for ziconotide‐ and placebo‐treated patients, respectively (p ≤ 0.001). During the initial titration phase, a significantly greater percentage of patients in the ziconotide group compared to the placebo group reported AEs, including abnormal gait, amblyopia, dizziness, nausea, nystagmus, pain, urinary retention, and vomiting. Conclusion. Ziconotide provided significant analgesia in patients for whom conventional therapy failed. However, there was a considerable incidence of ziconotide‐associated AEs due to the rapid titration and high doses administered. 相似文献
992.
993.
994.
Targeted silencing of disease-associated genes by synthetic short interfering RNA (siRNA) holds considerable promise as a novel therapeutic strategy. However, unmodified siRNA can be potent triggers of the innate immune response, particularly when associated with delivery vehicles that facilitate intracellular uptake. This represents a significant barrier to the therapeutic development of siRNA due to toxicity and off-target gene effects associated with this inflammatory response. Here we show that immune stimulation by synthetic siRNA can be completely abrogated by selective incorporation of 2'-O-methyl (2'OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex. These noninflammatory siRNA, containing less than 20% modified nucleotides, can be readily generated without disrupting their gene-silencing activity. We show that, coupled with an effective systemic delivery vehicle, 2'OMe-modified siRNA targeting apolipoprotein B (apoB) can mediate potent silencing of its target mRNA, causing significant decreases in serum apoB and cholesterol. This is achieved at therapeutically viable siRNA doses without cytokine induction, toxicity, or off-target effects associated with the use of unmodified siRNA. This approach to siRNA design and delivery should prove widely applicable and represents an important step in advancing synthetic siRNA into a broad range of therapeutic areas. 相似文献
995.
996.
997.
998.
999.
1000.